All GLG News Analyses Filed Under: Cardiology

I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...

I think the long affect of Aliskiren (3-4 days ) after the last pill is both a benefit and a risk; it is good in the setting on noncompliance but quite a challenge  when  trying to reverse  the hypotensive effects in  emergency situation. It is interesting that it is more effective...

While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these...

Novartis was able to show that combining tekturna with HCTZ provided significant improvement in blood pressure and did so safely.  They also showed that it provides better 24 hour coverage and coverage if patients miss a dose or take it late, this is a significant improvement over its competitors...

I have used both Tekturna and Tekturna/HCTZ and I have found the combination to be more effective than Tekturna itself.  But I do not think it is worth the extra expense.  You can get great reductions in BP with lotrel which is generic but much cheaper. Tekturna does reduce proteinuria but...

Atrial fibrillation management.  New anti-arrhythmic medication.  

Since its launch those involved in the treatment of hypertension have been hoping for more data on the effectiveness of Tekturna. Results of this study add evidence that the product is just beginning to solidly position itself in the antihyptertensive armamentarium, and is therefore encouraging. But...

It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.

 Study will be ridiculed.   1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.

Tecturna or Aliskerin belongs to the new anti hypertensive medication class of direct renin inhibitor. The basic action is to inhibit the renin angiotensin/aldosterone system. As we all have understanding of how ace-i and ARB act in this system at different points and effect the blood pressure,...